Zetia

PCSK9 inhibitors vastly over-priced, says ICER report

ICER's recommended price level would put Repatha and Praluent roughly in line with the price of Merck &Co's rival cholesterol drug Zetia (ezetimibe), which has been shown to be

Merck hopes for another Keytruda with new immunotherapy deal

But Merck has been hit by the on-going erosion to its cardiovascular and cholesterol drugs Zetia (ezetimibe) and Vytorin (ezetimibe/simvastatin). ... This is primarily due to loss of exclusivity of Zetia in Canada and declines of both products in the US.

Relief as study finds no cardiovascular risk with Januvia

Overall pharma sales fell 2% on the back of declines for cholesterol drugs Zetia (ezetimibe) and Vytorin (ezetimibe/simvastatin) as well as immunotherapeutic Remicade (infliximab) which is facing biosimilar competition in

PCSK9 inhibitor alirocumab works in statin-intolerance

Sanofi and Regeneron’s drug impresses at American Heart Association meeting. Sanofi and Regeneron's investigational drug alirocumab is more effective at reducing cholesterol levels than Merck &Co's Zetia in ... results of the IMPROVE-IT trial have now

Merck's ezetimibe has 'modest' benefit when added to statins

Vytorin and ezetimibe monotherapy Zetia got off to a strong start in the market but were quickly enveloped in controversy when the results of another study - called ENHANCE - failed to show ... Undeterred, Merck has said it will now file for approval of

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 [ Next 5 results ]